Why it’s hard to endure complaints from large pharmaceutical companies about Covid vaccine patent waivers Business News

The reaction of the pharmaceutical industry to the potentially groundbreaking decision by the United States to support a vaccine patent waiver in an effort to improve global supplies has never been the reaction of the pharmaceutical industry.

The pharmaceutical companies’ argument is this: innovation would be stifled, threatening the development of future treatments, and that would be disastrous for patients.

Do they have a point?